Pharmaceuticals, Vaccines
French multinational pharmaceutical + vaccines company (EPA: SAN; NASDAQ: SNY). Focus: immunology, rare diseases, neurology, oncology, vaccines. €44bn revenue 2023. 91,000+ employees. Sanofi Thailand operates innovative-medicines + vaccines (Sanofi Pasteur) portfolio.
Composite score across 5 categories MNCs operating in Thailand can demonstrate.
How this is computed: a weighted average of 5 sub-scores. Higher weight on signals an MNC has agency over (Thailand venue depth, international disclosure framework adoption, DEI policy explicitness) and lower weight on audit / scale signals that depend on company size.
How Sanofiis showing up for Thailand's LGBTQ+ community
Inclusion Dividend
Not yet enrolled
Creator partners
0
verified Thai KOLs
Audit history
No audit yet
Thailand presence
Single market presence
PrideShow LGBTQ+ ESG score (global) — Thailand-specific signals are above
86
Platinum · A+
LGBTQ+ Policy
100
Supply Chain
75
Community
70
Reporting
100
2023 Integrated Report — GRI / TCFD / CDP / SASB aligned
CDP Climate A-List
DJSI Europe + FTSE4Good Index constituent
Bloomberg Gender-Equality Index constituent
Sanofi Pride — LGBTQ+ ERG with 30+ country chapters
Planet Care — net-zero operations by 2030
Access to Medicines Index top-10
Signatory to UN Global Compact
Foundation S — humanitarian health programmes in 50+ countries
Transgender-inclusive healthcare in 40+ markets
Reach Sanofi's Thailand and APAC teams through PrideShow. Whether you're an NGO with a partnership idea, an SME on the supplier path, or a fellow MNC exploring co-activation — start the conversation here.
Is this your company?
Claim the listing to manage your Thailand inclusion evidence, respond to inbound enquiries, and connect with NGO and creator partners. Or sponsor PrideShow 2026 directly.
